Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 15Lung Neoplasms 5Neoplasms 4Sarcoma 3Sarcoma, Ewing 2Neuroendocrine Tumors 2Desmoplastic Small Round Cell Tumor 2Stomach Neoplasms 1SCLC, Extensive Stage 1Platinum-Resistant Lung Small Cell Carcinoma 1Ovarian Neoplasms 1Neutropenia 1Mesothelioma 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Malignancies 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Tumor 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 45Paclitaxel 42Carboplatin 34Bevacizumab 18Specimen Handling 17Letrozole 16lenvatinib 13Magnetic Resonance Spectroscopy 12dostarlimab 11Cisplatin 11Biopsy 11Taxes 10olaparib 9Fulvestrant 9Doxorubicin 9abemaciclib 8Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Surveys and Questionnaires 5Progestins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × PM 01183 × 1 year × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡